invest1 distinct publisher
GLP-1s moved testosterone and cycles in PMOS. The fight will be over which benefit pays
A small semaglutide trial reported endocrine gains, not just weight loss, in a condition affecting one in eight women. Fortune reports insurers are already putting up barriers.
Publishers:fortune.com
Reality
- Evidence34
- Adoption28
- Hype gap+22
- Incentives46
- Confidence38